Who Is Most at Risk for Pancreatitis When Taking GLP-1 Weight Loss Drugs?
Among 2,245 patients on GLP-1 drugs for obesity, 2.2% developed acute pancreatitis — gallstone disease and alcohol use were key risk factors.
Quick Facts
What This Study Found
Of 2,245 GLP-1 RA users for obesity, 2.2% developed acute pancreatitis; gallstone history and alcohol use were significant predictors.
Key Numbers
N=2,245; 49 cases (2.2%); gallstone disease aOR 2.9 (1.6-5.3); prior AP aOR 4.8 (1.8-13.2); CAD/PVD aOR 2.0 (1.01-3.9); tobacco aOR 2.4 (1.2-4.7); BMI 36-40 aOR 0.2 (0.06-0.6).
How They Did This
Retrospective case-control study with multivariable logistic regression to identify pancreatitis risk factors.
Why This Research Matters
Identifying who is at highest risk for pancreatitis on GLP-1 drugs allows clinicians to make safer prescribing decisions.
The Bigger Picture
Rather than avoiding GLP-1 drugs entirely due to pancreatitis fears, targeted risk assessment can guide safer prescribing.
What This Study Doesn't Tell Us
Retrospective design — may miss cases or confounders. Single-center study. The 2.2% rate may reflect the specific patient population.
Questions This Raises
- ?Should patients with gallstone history avoid GLP-1 drugs or just be monitored more closely?
- ?Does rapid weight loss from GLP-1 drugs increase gallstone-related pancreatitis risk?
Trust & Context
- Key Stat:
- 2.2% Rate of acute pancreatitis among 2,245 patients started on GLP-1 drugs for obesity
- Evidence Grade:
- Retrospective case-control — reasonable for identifying risk factors but incidence rates should be interpreted cautiously.
- Study Age:
- Published in 2025, providing timely safety data as GLP-1 prescriptions for obesity surge.
- Original Title:
- Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management.
- Published In:
- Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 25(5), 609-613 (2025)
- Database ID:
- RPEP-13093
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can GLP-1 drugs cause pancreatitis?
About 2.2% of patients in this study developed acute pancreatitis, with gallstone disease and alcohol use being the main risk factors.
Should I worry about pancreatitis on Wegovy or Ozempic?
Most patients tolerate GLP-1 drugs well. Discuss your risk factors, especially gallstone history and alcohol use, with your doctor before starting.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13093APA
Postlethwaite, Robert; Amin, Amin M; Alsawas, Rand; Almandoz, Jaime P; Sawas, Tarek. (2025). Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 25(5), 609-613. https://doi.org/10.1016/j.pan.2025.06.018
MLA
Postlethwaite, Robert, et al. "Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management.." Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2025. https://doi.org/10.1016/j.pan.2025.06.018
RethinkPeptides
RethinkPeptides Research Database. "Predictors of acute pancreatitis in patients treated with GL..." RPEP-13093. Retrieved from https://rethinkpeptides.com/research/postlethwaite-2025-predictors-of-acute-pancreatitis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.